Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00226330 · ClinicalTrials.gov registry record · Phase 3
GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
NCT00226330 is a Phase 3 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 1,100 participants.
The verdict
NCT00226330, a Phase 3 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
Study Summary
This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.
Interventions
- DRUG Pioglitazone
- DRUG Tesaglitazar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00226330
The ClinicalTrials.gov registry entry for NCT00226330 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00226330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00226330 about?
NCT00226330 is a clinical study titled "GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus". This is a parallel-group, multi-center, long-term extension study from the GALLANT 6 study to monitor the safety and tolerability of oral tesaglitazar compared with pioglitazone in patients with type 2 diabetes for up to 104 weeks of treatment. The total duration, including treatment and follow-up, ...
What is the current status of trial NCT00226330?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2005-03. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00226330?
The interventions under investigation include: Pioglitazone (DRUG), Tesaglitazar (DRUG).
Who is sponsoring clinical trial NCT00226330?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.